Longevity Is Now a Subscription Service — If You Can't Pay the Fee, You Get Cancelled Early

Looking at the immediate near term, the next six months may represent a genuine inflection point for anti-aging biotechnology. Retro Biosciences is scheduled to release Phase 1 clinical data for its Alzheimer's drug in August 2026, and if those early results are even modestly positive, the effect on the broader anti-aging sector will be significant. A company already valued at $1.8 billion delivering actual clinical proof-of-concept would accelerate venture capital flows into the entire longevity space at a pace we have not yet seen. Simultaneously, GLP-1 class drugs — already proven for obesity and type 2 diabetes — are being studied for cardiovascular, renal, and aging-related applications, and if even one major trial confirms a meaningful longevity benefit, the framing of aging as a "treatable medical condition" will gain enormous momentum in mainstream medicine. The critical question for the longevity divide is not whether these drugs will show promise — it is who will be able to afford them when they do. GLP-1 drugs currently run over $1,000 per month in the United States without insurance coverage, and the initial beneficiaries of any anti-aging breakthrough will be overwhelmingly concentrated among the wealthy.

There is a genuinely important policy signal sitting in sharp contrast to the billionaire biotech narrative, and it deserves far more attention than it is currently receiving. In June 2026, the World Economic Forum and Mercer jointly published data showing that low-cost prevention strategies — at a cost of just $1 to $40 per person — could prevent 400 million falls, 8.5 million type 2 diabetes cases, and 2.4 million dementia cases by 2040, saving $5.8 trillion in healthcare costs and generating $645 billion in productivity gains. Read that again: one to forty dollars per person in preventive investment, versus the $3 billion Jeff Bezos committed to a single cellular reprogramming laboratory. The contrast is not subtle. How governments respond to this report over the next six months will reveal whether the world's policymakers are treating longevity as a public good or a private luxury, and that response — or the absence of one — will set the course toward either a shared longevity dividend or a two-tiered lifespan reality.

In the medium term — roughly the next six months to two years — the anti-aging clinical pipeline will enter what I would call its moment of truth. Altos Labs began initial human safety testing in August 2025, but confirmed clinical efficacy data remains absent for cellular reprogramming technologies. Senolytic drugs — compounds designed to selectively clear aging "zombie" cells — are beginning Phase 2 and Phase 3 trials across multiple programs. This two-year window will likely determine which anti-aging interventions have genuine scientific credibility and which are sophisticated placebo effects with compelling narrative packaging. If the results are strong, the industry will expand explosively. But here is the uncomfortable reality about early-phase drug economics: even successful drugs arrive at sky-high price tags. The most advanced cancer therapies routinely exceed $100,000 per year, and some CAR-T treatments run $400,000 to $500,000 for a single course of treatment. Anti-aging drugs, absent extraordinary policy intervention at the regulatory and insurance level, will debut at similar price points, meaning the initial beneficiaries will be limited to the top 1% to 5% of the global wealth distribution.

The regulatory and insurance framework decisions made in this medium-term window may prove more consequential than the clinical trial results themselves. The pivotal question is whether anti-aging therapies will be classified as "disease treatments" — qualifying for health insurance coverage — or as "health enhancement" and "wellness products," which remain entirely self-pay by definition. Currently, the vast majority of countries do not formally classify aging as a disease. The WHO expanded aging-related codes in ICD-11, but stopped short of categorizing aging itself as a treatable pathology, and that classification matters enormously for access. Until that regulatory framing changes, anti-aging technology will remain in the category of luxury goods rather than medicine, purchased by the wealthy and unavailable to everyone else. With the global population aged 60 and over projected to reach 2.1 billion by 2050 — more than double today's figure — the outcome of this regulatory battle will directly affect billions of lives. OECD data already shows that the lowest-income quintile faces 2.5 times the unmet medical care needs of the highest quintile across 28 member countries, and without regulatory intervention actively driving access, the longevity divide will compound exponentially rather than slowly.

Looking further out toward 2028 to 2031, I think the data supports a genuinely alarming possibility: humanity may be entering the early stages of what I would call biological class divergence. When the anti-aging drug market grows from $19 billion in 2025 to $58 billion by 2035, the technological sophistication driving that growth does not stay static — it accelerates alongside the capital investment. Consider that Bryan Johnson is spending $2 million annually and already claims measurable biological age reversal at a level that was not possible even five years ago, and project that level of investment and iteration forward by a decade. A class of longevity aristocracy will emerge: individuals with life expectancies exceeding 100 years, biological ages maintained in their 50s, continuously accumulating wealth and political influence for decades longer than their less affluent contemporaries. On the other side of that divide, the majority will access only what public health infrastructure provides, and if Chetty's data is our guide — where the bottom 5% saw life expectancy grow by just 0.32 years over 14 years of technological progress — the outlook for the majority is bleak in the absence of structural intervention.

The long-term implications for democratic governance are perhaps the most troubling aspect of this entire trajectory, and they are almost entirely absent from public debate. In a society where lifespans diverge by 20 to 30 years based on wealth, "functional democracy" requires a definition that the political science textbooks have not yet written. A wealthy individual living to 120 casts votes in elections for 60 or more years. A poor person dying at 70 participates for 30 to 35 years — and those missing decades are not just fewer years of life but systematically smaller wealth accumulation, fewer electoral votes cast, less time for civic engagement, and reduced opportunity to benefit from the compounding returns that money generates over time. At a 7% annual return, the difference between 40 and 60 years of compounding is the difference between a 15-fold return and a 58-fold return — a 20-year lifespan advantage translates into roughly a four-fold amplification of accumulated wealth. "One person, one vote" describes a formal procedure; it does not describe the actual distribution of political power in a society where one class of citizens gets twice as many years to exercise that vote than another.

Now let me lay out three scenarios for where this goes, because I think the range of plausible futures is wider than most analysts acknowledge. The optimistic case — the bull scenario — is grounded in genuine historical precedent that deserves serious attention. Statins entered the market in 1987 at annual costs running into thousands of dollars; after patent expiration and generic competition, they became available for as little as four dollars per month. HIV antiretroviral therapies that once cost over $10,000 per year now reach patients across sub-Saharan Africa through generic manufacturing. If senolytic drugs or next-generation GLP-1 compounds hit patent expiration around 2035 to 2040 and go generic, combined with aggressive government adoption of the WEF and Mercer low-cost prevention framework at $1 to $40 per person, it is plausible that the global life expectancy gap could shrink from roughly 27 years today to under 15 years by 2050. I put the probability of this optimistic scenario at 20 to 25%: not impossible, but requiring an unusually high degree of coordination among governments, pharmaceutical companies, insurers, and international organizations simultaneously.

The base case — my modal probability at 50 to 55% — plays out like this. Global life expectancy continues to rise in line with IHME and Lancet projections: 4.9 additional years for men and 4.2 for women by 2050, with the largest absolute gains in lower-income nations, driving continued country-level convergence. But within wealthy nations, the income-stratified longevity gap holds steady or slowly expands. Anti-aging technology does not achieve meaningful proven clinical efficacy at scale until the 2040 to 2050 window, at which point initial accessible cohorts are the top 10 to 20% of global wealth. The Mass General Hospital research tells us that full wealth equalization could add 8.8 years to the poorest Americans' lives — but full wealth equalization remains deeply politically improbable in any major economy. The longevity divide stabilizes at levels roughly comparable to today, without dramatic deterioration or dramatic improvement. This is the muddle-through scenario: enough progress to avoid the absolute worst outcomes, nowhere near enough to produce anything resembling longevity equality.

The bear scenario — which I assign 20 to 25% probability but absolutely refuse to dismiss — unfolds as follows. Anti-aging technology succeeds clinically, but follows the oncology pricing precedent: annual costs exceed $100,000, making access possible only for well under 1% of the global population at initial commercialization. The World Inequality Database gives us the structural precondition for this outcome: the top 0.001% — fewer than 60,000 people globally — holds three times more wealth than the entire bottom half of humanity combined, and in almost every region, the top 1% owns more than the bottom 90% combined. That concentration of capital means technological access concentrates in precisely the same hands that are already funding this research. By 2050, the life expectancy gap between the longevity elite and everyone else does not shrink from 27 years — it expands to 35, 40, or beyond. Bryan Johnson spending $2 million per year on personal life extension stops being an eccentric outlier and becomes merely the entry fee for membership in the longevity upper class. This scenario is not science fiction; it is the direct logical extrapolation of current capital concentration trends into a world where anti-aging technology succeeds but remains unaffordable for most people.

I want to be honest about where I could be wrong, because intellectual honesty demands it. Anti-aging technology might democratize faster than any of my three scenarios predict — spreading like the smartphone, reaching 50% global adoption within a decade of clinical validation. Governments might surprise us, adopting longevity equity as a core policy agenda and mandating insurance coverage of anti-aging interventions before they ever reach luxury-product pricing. The technology itself might simply underperform, delivering modest life extension measured in a few years rather than decades, preventing any dramatic divergence in outcomes. I hold these possibilities open and I could be wrong about all of it.

But even granting all three optimistic corrections, the structural reality I keep returning to is this: wealth inequality is the deepest variable in the longevity equation, and it is not moving in a favorable direction in any major economy. The most immediate and scalable intervention is not a $3 billion biotech lab — it is the WEF and Mercer finding that $1 to $40 per person in preventive investment can prevent millions of cases of diabetes and dementia by 2040. The democratization of longevity begins not in a laboratory but in the decisions that policymakers make — right now, today — about where to direct public resources. Ask who your longevity technology serves, demand accountability on preventive care investment, and understand that lifespan equity is not a medical problem awaiting a scientific solution. It is a political choice we are actively making, every day, through inaction.